Recor Medical Supports New ESC Guidelines on Hypertension
The European Society of Cardiology (ESC) has recently released updated guidelines focused on managing high blood pressure and hypertension, placing a stronger emphasis on effective treatment options. Notably, they highlight the safety and efficacy of renal denervation, especially for patients struggling with uncontrolled hypertension.
Highlights of the Updated Guidelines
At the recent ESC Congress, the latest recommendations were presented. A key takeaway is that the guidelines recommend considering renal denervation (RDN) as a viable treatment option for patients with resistant hypertension or those at heightened risk for cardiovascular problems. This is particularly significant for individuals looking to explore alternatives to conventional medication.
Renal Denervation: A Safe Treatment
Renal denervation employs advanced technology to target overactive sympathetic nerves surrounding the renal arteries. There is growing evidence that this procedure not only helps lower blood pressure but also brings renewed hope to many patients who have not had success with standard hypertension treatments.
Expert Insights
Prof. Dr. Michael Böhm, a prominent cardiologist, spoke about the importance of these new guidelines. He pointed out that the ESC's recommendations are based on strong clinical trials that confirm the effectiveness and safety of renal denervation. He is committed to actively implementing these guidelines to enhance patient care.
The Global Challenge of Hypertension
Hypertension poses a significant global health challenge, affecting more than a billion people around the world. Often referred to as the "silent killer," it frequently goes undetected in many individuals until severe complications develop. Alarmingly, a large number of patients receiving treatment do not achieve adequate blood pressure control, highlighting the urgent need for more advanced treatment options.
Research and Development at Recor
Recor Medical, through its innovative approach, has developed the Paradise™ Ultrasound Renal Denervation (uRDN) system, which represents a breakthrough in managing hypertension. This unique system is designed to offer patients a powerful tool for effectively controlling their blood pressure.
Encouraging Clinical Trial Results
Built on a solid foundation of three globally conducted clinical trials involving over 500 patients, the Paradise uRDN system has shown promising results. Findings from the RADIANCE-HTN SOLO, RADIANCE-HTN TRIO, and RADIANCE II trials confirm both its effectiveness in reducing blood pressure and its positive safety profile.
Commitment to Progress
Since obtaining the CE mark in 2012, Recor has worked closely with the European cardiology community to incorporate uRDN therapy into broader hypertension treatment strategies. Their ongoing dedication is evident in their efforts to increase access to these innovative solutions.
Leadership Statements
Recor’s President and CEO, Lara Barghout, expressed her excitement about the ESC guidelines, acknowledging the pressing need to tackle uncontrolled hypertension on a global scale. She envisions a transformation in hypertension management, integrating advanced therapies like the Paradise uRDN system into treatment plans for those affected.
About Recor Medical, Inc.
Recor Medical operates under Otsuka Medical Devices Co., Ltd. and is committed to transforming hypertension management. The company's innovative work with the Paradise Ultrasound Renal Denervation system plays a crucial role in addressing hypertension. They are also involved in global registries and post-approval studies aimed at advancing their research and outreach efforts.
About Otsuka Medical Devices
Otsuka Medical Devices Co., Ltd. is dedicated to developing new therapeutic options, focusing on pioneering medical devices that meet unmet patient needs. The company thrives on innovation, prioritizing patient safety and effective treatment in its mission.
Frequently Asked Questions
What are the new ESC guidelines for hypertension management?
The ESC's new guidelines recommend renal denervation as an effective treatment for uncontrolled hypertension, emphasizing patient safety and appropriate selection.
What is renal denervation (RDN)?
RDN is a medical procedure that targets and disrupts overactive nerves around the renal arteries, aiming to lower blood pressure in patients who do not respond to medications.
How effective is the Paradise system by Recor Medical?
Clinical trials involving the Paradise uRDN system have yielded positive results, demonstrating significant blood pressure reduction and favorable safety profiles for patients with resistant hypertension.
What commitment does Recor Medical have toward hypertension treatment?
Recor Medical is dedicated to advancing hypertension management, focusing on innovative therapies like the Paradise system to improve patient outcomes globally.
Who can benefit from learning about these new guidelines?
Healthcare professionals, patients with uncontrolled hypertension, and anyone interested in cardiovascular health can gain valuable insights from these guidelines and the potential treatment options available.
